(I) GRAZAX - ProInvestor
(I) GRAZAX - ProInvestor
(I) GRAZAX - ProInvestor
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
May 2007 Revenue outlook for 2007<br />
Curing Allergy<br />
40<br />
Revenue is still forecast at DKKm 1,650-1,700<br />
Organic sales growth of allergy vaccines in the range of 15-19%<br />
<strong>GRAZAX</strong> ® sales forecast unchanged<br />
Significant uncertainty attached to <strong>GRAZAX</strong> ® forecast<br />
Price and reimbursement talks ongoing in a number of countries<br />
Anticipated seasonal variation in sales<br />
<strong>GRAZAX</strong> ® is still expected launched in Northern,<br />
Central and Southern Europe